NewsAI-assisted

Greenwich LifeSciences Secures Abstract Acceptances for Phase III FLAMINGO-01 Trial

Greenwich LifeSciences secures two SABCS 2026 abstract acceptances for its Fast Track-designated GLSI-100 Phase III breast cancer immunotherapy trial.

Vaibhavi M.
By Vaibhavi M.
Subject Matter Expert · Pharma Now
Nov 17, 2026Updated Nov 18, 2026 · 2 min read
Greenwich LifeSciences Secures Abstract Acceptances for Phase III FLAMINGO-01 Trial
AI-assisted reporting
Reviewed by Vaibhavi M., Subject Matter Expert · Pharma Now
80/ 100
Trust score
High confidence

Two abstracts from the FLAMINGO-01 Phase III trial have been accepted for presentation at the San Antonio Breast Cancer Symposium, signaling that Greenwich LifeSciences' GP2 immunotherapy program is generating sufficient clinical data to warrant peer scrutiny at the field's most-watched oncology forum. For development operations and regulatory affairs teams tracking late-stage immunotherapy pipelines, the December presentations offer an early read on trial design robustness and enrollment progress.

Greenwich LifeSciences confirmed both abstracts will appear as poster presentations on December 9, 2026, during the ongoing clinical trials and late-breaking abstracts sessions at SABCS 2026, held December 8–11 in San Antonio. The Steering Committee of FLAMINGO-01 authored both posters, and the company will publish them on its website when SABCS embargo protocols permit.

GLSI-100, the investigational agent under evaluation in FLAMINGO-01, carries FDA Fast Track designation, a status that compresses the agency's review timeline and opens rolling submission pathways. For manufacturing and quality teams, Fast Track designation is a relevant planning signal: if Phase III data support a Biologics License Application, the compressed review window narrows the lead time available to validate commercial-scale production processes, qualify suppliers, and establish sterility assurance protocols consistent with 21 CFR Part 211 and ICH Q10 quality system expectations.

GP2 is a 9-amino-acid transmembrane peptide derived from the HER2 protein, which is expressed at low, intermediate, or high levels in approximately 75% of breast cancers. The FLAMINGO-01 trial is evaluating GP2 as a recurrence-prevention immunotherapy in patients who have previously undergone surgery, a population and endpoint combination that carries distinct CMC and cold-chain considerations relative to acute-treatment biologics.

Approximately 10,000 healthcare professionals from more than 105 countries are expected to attend SABCS 2026, making the December poster sessions a practical opportunity for clinical operations and regulatory leads to benchmark FLAMINGO-01's design against competing late-stage breast cancer programs presented at the same venue.

The December 9 poster sessions will serve as the first public, peer-reviewed presentation of FLAMINGO-01 data under SABCS scrutiny, with commercial-readiness planning contingent on the clinical and safety findings disclosed.

Source: Greenwich LifeSciences, Inc. via GlobeNewswire, November 17, 2026.

Read the original release ↗
TopicsNews
Vaibhavi M.
Written by
Vaibhavi M.
Subject Matter Expert · Pharma Now

Reporting on the science, business and regulation shaping the pharmaceutical industry.

Discussion

Loading discussion…

More from Pharma News

All stories →